Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of atrial fibrillation on clinical outcomes among patients with coronary artery disease undergoing revascularisation with drug-eluting stents.
Pilgrim T, Kalesan B, Zanchin T, Pulver C, Jung S, Mattle H, Carrel T, Moschovitis A, Stortecky S, Wenaweser P, Stefanini GG, Räber L, Meier B, Jüni P, Windecker S. Pilgrim T, et al. Among authors: kalesan b. EuroIntervention. 2013 Jan 22;8(9):1061-71. doi: 10.4244/EIJV8I9A163. EuroIntervention. 2013. PMID: 23339812 Free article.
Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study.
Simsek C, Räber L, Magro M, Boersma E, Onuma Y, Stefanini GG, Zanchin T, Kalesan B, Wenaweser P, Jüni P, van Geuns RJ, van Domburg RT, Windecker S, Serruys PW. Simsek C, et al. Among authors: kalesan b. Int J Cardiol. 2013 Dec 5;170(1):36-42. doi: 10.1016/j.ijcard.2013.10.006. Epub 2013 Oct 12. Int J Cardiol. 2013. PMID: 24196314
Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial.
Räber L, Wohlwend L, Wigger M, Togni M, Wandel S, Wenaweser P, Cook S, Moschovitis A, Vogel R, Kalesan B, Seiler C, Eberli F, Lüscher TF, Meier B, Jüni P, Windecker S. Räber L, et al. Among authors: kalesan b. Circulation. 2011 Jun 21;123(24):2819-28, 6 p following 2828. doi: 10.1161/CIRCULATIONAHA.110.004762. Epub 2011 Jun 6. Circulation. 2011. PMID: 21646500 Clinical Trial.
Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial.
Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, van Es GA, Meier B, Windecker S, Jüni P. Stefanini GG, et al. Among authors: kalesan b. Lancet. 2011 Dec 3;378(9807):1940-8. doi: 10.1016/S0140-6736(11)61672-3. Epub 2011 Nov 8. Lancet. 2011. PMID: 22075451 Free article. Clinical Trial.
Clinical outcomes of patients with severe aortic stenosis at increased surgical risk according to treatment modality.
Wenaweser P, Pilgrim T, Kadner A, Huber C, Stortecky S, Buellesfeld L, Khattab AA, Meuli F, Roth N, Eberle B, Erdös G, Brinks H, Kalesan B, Meier B, Jüni P, Carrel T, Windecker S. Wenaweser P, et al. Among authors: kalesan b. J Am Coll Cardiol. 2011 Nov 15;58(21):2151-62. doi: 10.1016/j.jacc.2011.05.063. J Am Coll Cardiol. 2011. PMID: 22078420 Free article. Clinical Trial.
Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study.
Räber L, Magro M, Stefanini GG, Kalesan B, van Domburg RT, Onuma Y, Wenaweser P, Daemen J, Meier B, Jüni P, Serruys PW, Windecker S. Räber L, et al. Among authors: kalesan b. Circulation. 2012 Mar 6;125(9):1110-21. doi: 10.1161/CIRCULATIONAHA.111.058560. Epub 2012 Feb 1. Circulation. 2012. PMID: 22302840
117 results